Press release
Hypertriglyceridemia Pipeline Analysis Demonstrates Novel 22+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
In the Hypertriglyceridemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Hypertriglyceridemia clinical trials studies, Hypertriglyceridemia NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Hypertriglyceridemia Pipeline Insight Report
• DelveInsight's Hypertriglyceridemia pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Hypertriglyceridemia treatment.
• The leading Hypertriglyceridemia Companies includes Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Acasti Pharma Inc., Staten Biotechnology BV, NorthSea Therapeutics B.V., Afimmune, Rivus Pharmaceuticals, Novo Nordisk, Viking Therapeutics, Liminal BioSciences, Matinas BioPharma, Arbutus Biopharma, Better Therapeutics, and others.
• Promising Hypertriglyceridemia Pipeline Therapies includes CaPre (TM), Volanesorsen, Omega 3 pentaenoic acid, icosapent ethyl, ISIS 678354, Diazoxide choline, Phytosterol esters of omega-3, APOC-III-L-Rx, evinacumab, and others.
• The Hypertriglyceridemia Companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The Hypertriglyceridemia pipeline therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.
To explore more information on the latest breakthroughs in the Hypertriglyceridemia Pipeline treatment landscape of the report, click here Hypertriglyceridemia Pipeline Outlook @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hypertriglyceridemia Overview
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the "good" cholesterol, HDL (high-density lipoprotein).
Hypertriglyceridemia Emerging Drugs Profile
ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.
MND-21: Mochida Pharmaceutical
MND-21, a therapeutic agent for hypertriglyceridemia which is being developed in collaboration with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. in China. Currently, it is in Phase III stage of clinical trial evaluation to treat Hypertriglyceridaemia.
For further information, refer to the detailed Hypertriglyceridemia Unmet Needs, Hypertriglyceridemia Market Drivers, and Hypertriglyceridemia Market Barriers, click here for Hypertriglyceridemia Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hypertriglyceridemia Pipeline Therapeutics Assessment
There are approx. 22+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Mochida Pharmaceutical.
Hypertriglyceridemia Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Hypertriglyceridemia Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Request a sample and discover the recent advances in Hypertriglyceridemia Ongoing Clinical Trial Analysis and Medications, click here for Hypertriglyceridemia Treatment Landscape @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hypertriglyceridemia Pipeline Report
• Coverage- Global
• Hypertriglyceridemia Companies- Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Acasti Pharma Inc., Staten Biotechnology BV, NorthSea Therapeutics B.V., Afimmune, Rivus Pharmaceuticals, Novo Nordisk, Viking Therapeutics, Liminal BioSciences, Matinas BioPharma, Arbutus Biopharma, Better Therapeutics, and others.
• Hypertriglyceridemia Pipeline Therapies- CaPre (TM), Volanesorsen, Omega 3 pentaenoic acid, icosapent ethyl, ISIS 678354, Diazoxide choline, Phytosterol esters of omega-3, APOC-III-L-Rx, evinacumab, and others.
• Hypertriglyceridemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Hypertriglyceridemia Market Drivers and Hypertriglyceridemia Market Barriers, click here for Hypertriglyceridemia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hypertriglyceridemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypertriglyceridemia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MND-21: Mochida Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ARO-APOC3: Arrowhead Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ARGX 116: argenx
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. VK 1430: Viking Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hypertriglyceridemia Key Companies
21. Hypertriglyceridemia Key Products
22. Hypertriglyceridemia- Unmet Needs
23. Hypertriglyceridemia- Market Drivers and Barriers
24. Hypertriglyceridemia- Future Perspectives and Conclusion
25. Hypertriglyceridemia Analyst Views
26. Hypertriglyceridemia Key Companies
27. Appendix
Got Queries? Find out the related information on Hypertriglyceridemia Mergers and acquisitions, Hypertriglyceridemia Licensing Activities and Hypertriglyceridemia Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertriglyceridemia Pipeline Analysis Demonstrates Novel 22+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight here
News-ID: 2926611 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Hypertriglyceridemia
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Hypertriglyceridemia Therapeutics Market Detailed In New Research Report 2024 |S …
The most recent report published by CMI indicates that the "Hypertriglyceridemia Therapeutics Market 2024-2031" is likely to accelerate significantly in the next few years. The Hypertriglyceridemia Therapeutics Market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The Hypertriglyceridemia Therapeutics Market study includes information on market factors such as the market dynamics, drivers, restraints,…
Hypertriglyceridemia Treatment Market Growing Rapidly by - Hikma Pharmaceuticals …
DataM Intelligence has published a new research report on "Hypertriglyceridemia Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia Treatment Market Size, Share, Trends, Growth, Volume and Fo …
The Hypertriglyceridemia Treatment Market is expected to grow at a high CAGR during the forecast period 2023-2030. North America region has the highest market share in the Hypertriglyceridemia Treatment Market, and it is further continuing its dominance during the forecast period.
Browse Full Report at: https://www.datamintelligence.com/research-report/hypertriglyceridemia-treatment-market
Our research report gives wide perceptions of the latest trends and development prospects of the market analysis, detailed segmentation analysis, volume, size, share, growth drives, and…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
